Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
ARS Pharmaceuticals (SPRY)
NASDAQ:SPRY
Holding SPRY?
Track your performance easily
SPRY Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$4.94 - $18.51
Previous Close$14.51
Volume383.07K
Average Volume (3M)1.06M
Market Cap
$1.41B
Enterprise Value$1.21B
Total Cash (Recent Filing)$204.62M
Total Debt (Recent Filing)$102.00K
Price to Earnings (P/E)―
Beta2.11
Next Earnings
Mar 20, 2025EPS Estimate
-$0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.51
Shares Outstanding97,185,475
10 Day Avg. Volume1,709,882
30 Day Avg. Volume1,055,897
Standard Deviation0.21
R-Squared0.04
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)6.55
Price to Sales (P/S)521.88
Price to Cash Flow (P/CF)-23.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue469.49
Enterprise Value/Gross Profit40.19K
Enterprise Value/Ebitda-19.35
Forecast
1Y Price Target
$30.00Price Target Upside106.75% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
ARS Pharmaceuticals News
PremiumCompany Announcements
ARS Pharmaceuticals’ Strong Q3 2024 Highlights
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
SPRY FAQ
What was ARS Pharmaceuticals’s price range in the past 12 months?
ARS Pharmaceuticals lowest stock price was $4.94 and its highest was $18.51 in the past 12 months.
What is ARS Pharmaceuticals’s market cap?
Currently, no data Available
When is ARS Pharmaceuticals’s upcoming earnings report date?
ARS Pharmaceuticals’s upcoming earnings report date is Mar 20, 2025 which is in 89 days.
How were ARS Pharmaceuticals’s earnings last quarter?
ARS Pharmaceuticals released its earnings results on Nov 13, 2024. The company reported -$0.2 earnings per share for the quarter, missing the consensus estimate of -$0.142 by -$0.058.
Is ARS Pharmaceuticals overvalued?
According to Wall Street analysts ARS Pharmaceuticals’s price is currently Undervalued.
Does ARS Pharmaceuticals pay dividends?
ARS Pharmaceuticals does not currently pay dividends.
What is ARS Pharmaceuticals’s EPS estimate?
ARS Pharmaceuticals’s EPS estimate is -$0.06.
How many shares outstanding does ARS Pharmaceuticals have?
ARS Pharmaceuticals has 97,185,480 shares outstanding.
What happened to ARS Pharmaceuticals’s price movement after its last earnings report?
ARS Pharmaceuticals reported an EPS of -$0.2 in its last earnings report, missing expectations of -$0.142. Following the earnings report the stock price went down -15.232%.
Which hedge fund is a major shareholder of ARS Pharmaceuticals?
Among the largest hedge funds holding ARS Pharmaceuticals’s share is Deerfield Management Company, LP. It holds ARS Pharmaceuticals’s shares valued at 161M.
---
ARS Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$30.00 (106.75% Upside)
$30.00 (106.75% Upside)
Blogger Sentiment
Bullish
SPRY Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 938.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $11.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 0.9%
Last 30 Days ▼ 0.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
202.29%
12-Months-Change
Fundamentals
Return on Equity
-22.41%
Trailing 12-Months
Asset Growth
-12.45%
Trailing 12-Months
Company Description
ARS Pharmaceuticals
Silverback Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on leveraging its ImmunoTAC technology platform to develop tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases.
---
SPRY Earnings Call
Q3 2024
0:00 / 0:00
---
SPRY Stock 12 Month Forecast
Average Price Target
$30.00
▲(106.75% Upside)
Technical Analysis
Best Analysts Covering SPRY
1 Year
1 Year Success Rate
8/10 ratings generated profit
1 Year Average Return
+109.21%
assigned a buy rating 10 months ago
Copying Andreas Argyrides's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +109.21% per trade.
---